Achondroplasia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Achondroplasia is characterized by disproportionate short stature associated with an enlarged head, depressed nasal bridge, short stubby trident hands, lordotic lumbar spine, prominent buttocks and protuberant abdomen. This autosomal-dominant disorder is caused by mutations in the type 3 receptor for a fibroblast growth factor (FGFR3). During pregnancy, the diagnosis of achondroplasia may be suspected in the third trimester by abnormal ultrasound findings, namely foreshortening of the limbs (95th percentile) and low nasal bridge. This can lead to intra-uterine imaging. Antenatal radiographic features of achondroplasia are shortened long bones with wide metaphyses and a slim and radiolucent area in the proximal femur and horizontal acetabular roof. After birth, achondroplasia is clinically characterized by short limbs, especially the proximal segment, with a long trunk and a narrow thorax. Birth height is generally preserved. The head is large with frontal bossing, possibly leading to obstetric difficulties. The midface is hypoplastic, resulting in an endochondral growth defect at the base of the skull. Hands and fingers are short with a trident appearance in early life due to the inability to fully oppose the third and fourth digits.
- Achondroplasia arises in about 1 in every 25,000 to 30,000 individuals. That, in turn, translates into around 250,000 affected persons worldwide.
Thelansis’s “Achondroplasia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Achondroplasia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Achondroplasia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Achondroplasia Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment